Oracle Falls, American Express Surges, Eli Lilly Falls on 'Cheap Weight Loss Dugs'

On this episode of Stock Movers:

- Oracle (ORCL) fell after giving its long-range financial outlook, suggesting investors anticipated a bigger boost from its investment in AI infrastructure. The company said overall annual revenue would total $225 billion by fiscal 2030, and the cloud infrastructure business would produce $144 billion in sales by then. Investors have expressed concern about the profitability of Oracle's AI effort, but the company said an infrastructure project for AI would have a gross margin of 35%.

- American Express (AXP) reported earnings that beat expectations after unveiling the long-anticipated Platinum credit card refresh last month. Initial demand for the revamped Platinum card exceeded the firm’s predictions, with US Platinum account acquisitions doubling from pre-refresh levels. The firm raised the lower end of its full-year guidance, with revenue now expected to grow 9% to 10% and earnings likely to total $15.20 to $15.50 a share.

- Eli Lilly (LLY) and Novo Nordisk shares fell after President Donald Trump said the price of the diabetes drug Ozempic could come down to just $150 a month. Trump told reporters that the cost of the drug will soon be “much lower” than the current US list price of roughly $1,000 for a month’s supply. The potential price cut could lead to a big hit for Novo and Lilly, which dominate a market expected to top $95 billion by 2030

See omnystudio.com/listener for privacy information.